Heron Therapeutics Inc (HRTX) FinancialsHRTXHeron Therapeutics Inc

Heron Therapeutics Inc (HRTX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is CINVANTI, accounting for 57.9% of total sales, equivalent to $21.79M. Other significant revenue streams include ZYNRELEF and APONVIE. Understanding this composition is critical for investors evaluating how HRTX navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Heron Therapeutics Inc maintains a gross margin of 69.28%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -5.43%, while the net margin is -14.57%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively HRTX converts its operational activities into shareholder value.

In the context of the broader market, HRTX competes directly with industry leaders such as PLRX and HYFT. With a market capitalization of $53.16M, it holds a leading position in the sector. When comparing efficiency, HRTX's gross margin of 69.28% stands against PLRX's N/A and HYFT's 58.58%. Such benchmarking helps identify whether Heron Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Heron has shown declining revenue trends with a 20.24% drop over the last 20 days and a staggering 76.58% decline year-to-date. The gross margin has also decreased to 69.28% in Q2 2026, down from previous quarters, indicating pressures on profitability.